The importance of early treatment of the anaemia of chronic kidney disease

被引:21
|
作者
Eknoyan, G [1 ]
机构
[1] Baylor Coll Med, Dept Med, Renal Sect, Houston, TX 77030 USA
关键词
anaemia; cardiovascular diseased; chronic kidney disease; chronic renal failure; dialysis morbidity; dialysis mortality; epoetin; erythropoietin; kidney failure;
D O I
10.1093/ndt/16.suppl_5.45
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
The beneficial effects of treating the anaemia of dialysis-dependent patients with erythropoietin on the improvement of cardiac status, exercise capacity, cognitive function and quality of life are well established. Equally, if not more important is the reduction in morbidity and mortality that accompanies the treatment of anaemia with epoietin. These documented improvements in outcomes of care notwithstanding, mortality and morbidity due to cardiovascular disease (CVD) remain high in dialysis patients. Recent epidemiological evidence indicates that: (i) the prevalence of CVD is very high in patients at the start of dialysis (ii) pre-existing CVD is the major risk factor for mortality and morbidity on dialysis; (iii) CVD begins early in the course of kidney disease, shows an inverse relationship to kidney function and increases in prevalence and severity with progression of kidney disease; and (iv) corrective measures, which take 3-5 years to show a favourable effect, must be instituted well before the initiation of dialysis. Hypertension and anaemia, which develop in the course of progressive reduction in kidney function, are the principal risk factors for the prevalence of left ventricular hypertrophy (LVH) in those with chronic kidney disease, and their treatment has been shown to arrest or reverse LVH in these individuals. Whereas the treatment of hypertension early in the course of kidney disease has been incorporated into clinical practice, there has been reluctance in the treatment of anaemia because of the possibility of worsening kidney function with epoietin, as shown in rats. There is now convincing evidence that epoietin has no potential adverse effect on kidney function in humans. While the most compelling reason for the early treatment of the anaemia of kidney disease is its beneficial effect on cardiovascular function, other documented potential benefits are improvements in exercise capacity, cognitive function and quality of life.
引用
收藏
页码:45 / 49
页数:5
相关论文
共 50 条
  • [21] Managing anaemia in kidney transplant patients with chronic kidney disease
    Lopez Oliva, Maria Ovidia
    del Castillo Caba, Domingo
    Fresnedo, Gema Fernandez
    NEFROLOGIA, 2009, 29 : 25 - 30
  • [22] Features Importance to Improve Interpretability of Chronic Kidney Disease Early Diagnosis
    Moreno-Sanchez, Pedro A.
    2020 IEEE INTERNATIONAL CONFERENCE ON BIG DATA (BIG DATA), 2020, : 3786 - 3792
  • [23] CHRONIC KIDNEY DISEASE (CKD): THE SILENT EPIDEMIC. THE IMPORTANCE OF EARLY DETECTION AND TREATMENT ON THE PREVENTION OF CKD
    Arikan, Hakki
    Koc, M.
    MARMARA MEDICAL JOURNAL, 2005, 18 (02): : 93 - 100
  • [24] Pathogenesis and treatment of anaemia of chronic disease
    Weiss, G
    BLOOD REVIEWS, 2002, 16 (02) : 87 - 96
  • [25] Results of a Survey on the Importance and Treatment of metabolic Acidosis in chronic Kidney Disease
    Geiger, H.
    Buettner, S.
    INTERNIST, 2013, 54 : 110 - 111
  • [26] Anaemia management and mortality risk in chronic kidney disease
    Hoerl, Walter H.
    NATURE REVIEWS NEPHROLOGY, 2013, 9 (05) : 291 - 301
  • [27] Gastrointestinal lesions in chronic kidney disease patients with anaemia
    Garcia Agudo, Rebeca
    Aoufi Rabih, Sami
    Gonzalez Carro, Pedro
    Perez Roldan, Francisco
    Proy Vega, Beatriz
    Arias Arias, Angel
    Cazalla Cadenas, Fatima
    Tenias Burillo, Jose Maria
    Fernandez Rodriguez, Ana
    NEFROLOGIA, 2019, 39 (01): : 50 - 57
  • [28] Anaemia management and mortality risk in chronic kidney disease
    Walter H. Hörl
    Nature Reviews Nephrology, 2013, 9 : 291 - 301
  • [29] Diabetes mellitus and anaemia in patients with chronic kidney disease
    Lejnieks, A.
    Kuzema, V.
    Petersons, A.
    DIABETOLOGIA, 2008, 51 : S485 - S485
  • [30] Iron therapy for managing anaemia in chronic kidney disease
    Macdougall, Iain C.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2018, 27 (05): : 358 - 363